Abstract
Over the last decade, the ‘traditional’ drug scene has been supplemented – but not replaced – by the emergence of a range of novel psychoactive substances (NPS), which are either newly created or existing drugs, including medications, now being used in novel ways. By the end of 2014, in excess of 500 NPS had been reported by a large number of countries in the world. Most recent data show, however, that synthetic cathinones, synthetic cannabinoids, and psychedelics/phenethylamines account for the largest number of NPS.
The present chapter aims at providing an overview of the clinical and pharmacological issues relating to these most popular NPS categories. Given the vast range of medical and psychopathological issues associated with the molecules here described, it is crucial for health professionals to be aware of the effects and toxicity of NPS. A general overview of the acute management of NPS adverse events is provided as well, although further studies are required to identify a range of evidence-based, index molecule-focused, treatment strategies. The rapid pace of change in the NPS online market constitutes a major challenge to the provision of current and reliable scientific knowledge on these substances.
Keywords
This is a preview of subscription content, log in via an institution.
References
UNODC (United Nations Office on Drugs and Crime) (2015) World Drug Report. https://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf. Accessed 30 Nov 2015
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2015) New psychoactive substances in Europe - an update from the EU Early Warning System. Publications Office of the European Union, Luxembourg. http://www.emcdda.europa.eu/publications/2015/new-psychoactive-substances. Accessed 15 Nov 2015
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2015) Synthetic cannabinoids in Europe. http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids. Accessed 29 Nov 2015
Daly M (2013) Streets legal. Druglink 28:17
Shlosberg D, Zalsman G, Shoval G (2014) Emerging issues in the relationship between adolescent substance use and suicidal behavior. Isr J Psychiatry Relat Sci 51:262–267
Auwarter V, Dargan PI, Wood DM (2013) Synthetic cannabinoid receptor agonists. In: Dargan PI, Wood DM (eds) Novel psychoactive substances classification, pharmacology and toxicology. Elsevier, London, pp 317–343
Schifano F, Corazza O, Davey Z, Di Furia L, Farre M, Flesland L, Mannonen M, Pagani S, Peltoniemi T, Pezzolesi C, Scherbaum N, Siemann H, Skutle A, Torrens M, Van Der Kreeft P (2009) Psychoactive drug or mystical incense? Overview of the online available information on Spice products. Int J Cult Ment Health 2:137–144
Thomas BF, Wiley JL, Pollard GT, Grabenauer M (2014) Cannabinoid designer drugs: effects and forensics. In: Pertwee RG (ed) Handbook of cannabis. Oxford University Press, Oxford, pp 710–729
Schifano F, Orsolini L, Papanti GD, Corkery J (2015) Novel psychoactive substances of interest for psychiatry. World Psychiatry 14:15–26
Martinotti G, Lupi M, Acciavatti A, Cinosi E, Santacroce R, Signorelli MS, Bandini L, Lisi G, Quattrone D, Ciambrone P, Aguglia A, Pinna F, Calò S, Janiri L, di Giannantonio M (2014) Novel psychoactive substances in young adults with and without psychiatric comorbidities. Biomed Res Int. doi:10.1155/2014/815424
Naviglio S, Papanti D, Moressa V, Ventura A (2015) An adolescent with an altered state of mind. BMJ 350:h299
Vento AE, Martinotti G, Cinosi E (2014) Substance use in the club scene of Rome: a pilot study. Biomed Res Int 2014:617546
Appendino G, Minassi A, Taglialatela-Scafati O (2014) Recreational drug discovery: natural products as lead structures for the synthesis of smart drugs. Nat Prod Rep 31:880–904
Abdulrahim D, Bowden-Jones O, on behalf of the NEPTUNE Expert Group (2015) Overview of the effects and harms of club drugs. In: Guidance on the Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances. Novel Psychoactive Treatment UK Network (NEPTUNE), London.
Papanti D, Orsolini L, Francesconi G, Schifano F (2014) ‘Noids’ in a nutshell: everything you (don’t) want to know about synthetic cannabimimetics. Adv Dual Diagn 7:137–148
Brents LK, Prather PL (2014) The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev 46:72–85
Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Handsen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62:588–631
Pertwee RG (2009) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17:1360–1381
Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL (2013) Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity? Life Sci 97:45–54
Lewin AH, Seltzman HH, Carroll FI, Mascarella SW, Reddy PA (2013) Emergence and properties of spice and bath salts: a medicinal chemistry perspective. Life Sci 97:9–19
Halberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioural effects of indoleamine hallucinogens. Neuropharmacology 61:364–381
Wells DL, Ott CA (2011) The new marijuana. Ann Pharmacother 45:414–417
Fisar Z (2010) Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol 381:563–572
Ismail F (2002) Important fluorinated drugs in experimental and clinical use. J Fluor Chem 118:27–33
Wilkinson SM, Banister SD, Kassiou M et al (2015) Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Aust J Chem 68:4–8
Baggaley K (2015) Drugs by design: corrupt chemists tweak compounds faster than law enforcement can call them illegal. Sci News 187:22–25
Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, Impagnatiello M, Pascolo-Fabrici E, Bonavigo T (2013) “Spiceophrenia’: a systematic overview of ‘Spice’-related psychopathological issues and a case report. Hum Psychopharmacol 28:379–389
Winstock AR, Barratt MJ (2013) Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 1:106–111
Spaderna M, Addy PH, D’Souza DC (2013) Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) 228:525–540
Wessinger WD, Moran JH, Seely KA (2015) Synthetic cannabinoid effects on behavior and motivation. In: Campolongo P, Fattore L (eds) Cannabinoid modulation of emotion, memory, and motivation. Springer, New York, pp 205–224
Wood DM, Dargan PI (2012) Mephedrone (4-methylmethcathinone): what is new in our understanding of its use and toxicity. Prog Neuropsychopharmacol Biol Psychiatry 39:227–233. doi:10.1016/j.pnpbp.2012.04.020
Wood DM, Dargan PI (2012) Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monit 34:363–367
Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108:534–544
Winstock AR, Barratt MJ (2013) The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol 28:390–393
Freeman MJ, Rose DZ, Myers MA (2013) Ischemic stroke after use of the synthetic marijuana ‘Spice’. Neurology 81:2090–2093
Hopkins CY, Gilchrist BL (2013) A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med 45:544–546
Louh IK, Freeman WD (2014) A ‘spicy’ encephalopathy: synthetic cannabinoids as cause of encephalopathy and seizure. Crit Care 18:553
Mir A, Obafemi A, Young A et al (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128:e1622–e1627
Rose DZ, Guerrero WR, Mokin MV (2015) Haemorrhagic stroke following use of the synthetic marijuana “spice”. Neurology 85:1177–1179
Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2015) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol 54:1–13. doi:10.3109/15563650.2015.1110590
CDC (2012) Acute kidney injury associated with synthetic cannabinoid use – multiple states. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 62:93–98
Kasper AM, Ridpath AD, Arnold JK, Chatham-stephens K, Morrison M, Olayinka O, Parker C, Galli R, Cox R, Pteacely N, Anderson J, Kyle PB, Gerona R, Martin C, Schier J, Wolkin A, Dobbs T (2015) Severe illness associated with reported use of synthetic cannabinoids - Mississippi, April 2015. MMWR Morb Mortal Wkly Rep 64:1121–1122
Sheikh A, Lukšič M, Ferstenberg R, Culpepper-Morgan JA (2014) SPICE/K2 synthetic Marijuana-induced toxic hepatitis treated with N-acetylcysteine. Am J Case Rep 15:584–588
Spengler E, LaBrecque D (2014) A case of acute liver failure associated with synthetic cannabis use. American College of Gastroenterology Annual Scientific Meeting Abstracts, Philadelphia
Sweeney B, Talebi S, Toro D, Gonzalez K, Menoscal JP, Shaw R, Hassen GW (2015) Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med 34:121.e1-2; doi:10.1016/j.ajem.2015.05.052
Tyndall JA, Gerona R, De Portu G et al (2015) An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol 3:950–956. doi:10.3109/15563650.2015.1100306
Alhadi S, Tiwari A, Vohra R (2013) High times, low SATS: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol 9:199–206
Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL (2012) ‘Spice’ and ‘K2’ herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 21:320–326
Froberg BA, Bauer BD (2012) Pneumorachis, pneumomediastinum, and subcutaneous emphysema after synthetic cannabinoid use. Clin Toxicol 50:705
Macfarlane V, Christie G (2015) Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 34:147–153
Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, Bianconi F, Gardner-Sood P, O’Connor J, Russo M, Stilo SA, Margues TR, Mondelli V, Dazzan P, Pariante C, David AS, Gaughran F, Atakan Z, Iyegbe C, Powell J, Morgan C, Lynskey M, Murray RM (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2:233–238
Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM (2009) High-potency cannabis and the risk of psychosis. Br J Psychiatry 195:488–491
Brakoulias V (2012) Products containing synthetic cannabinoids and psychosis. Aust N Z J Psychiatry 46:281–282
Glue P, Al-Shaqsi S, Hancock D, Gale C, Strong B, Schep L (2013) Hospitalisation associated with use of the synthetic cannabinoid K2. N Z Med J 126:18–23
Celofiga A, Koprivsek J, Klavz J (2014) Use of synthetic cannabinoids in patients with psychotic disorders: case series. J Dual Diagn 10:168–173
Oluwabusi OO, Lobach L, Akhtar U, Youngman B, Ambrosini PJ (2012) Synthetic cannabinoid-induced psychosis: two adolescent cases. J Child Adolesc Psychopharmacol 22:393–395
Ustundag MF, Ozhan Ibis E, Yucel A, Ozcan H (2015) Synthetic cannabis-induced mania. Case Rep Psychiatry 2015:310930. doi:10.1155/2015/310930
Lászik A, Törő K, Vannai M, Sára-Klausz g, Kócs t, Farkas R, Keller É, Róna K (2015) Self inflicted fatal injuries in association with synthetic cannabinoid abuse. 24th International Meeting on Forensic Medicine Alpe-Adria-Pannonia, AAP 2015 Programme and Abstract Book
Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH (2013) K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci 58:1676–1680. doi:10.1111/1556-4029.12216
Rosenbaum CD, Carreiro SP, Babu KM (2012) Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 8:5–32. doi:10.1007/s13181
Shanks KG, Dahn T, Terrell AR (2012) Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol 36:145–152. doi:10.1093/jat/bks013
Trecki J, Gerona RR, Schwartz MD (2015) Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373:103–107
Rickli A, Hoener MC, Liechti ME (2015) Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 25:365–376. doi:10.1016/j.euroneuro.2014.12.012
McElrath K, O’Neill C (2011) Experiences with mephedrone pre-and post-legislative controls: perceptions of safety and sources of supply. Int J Drug Policy 22:120–127. doi:10.1016/j.drugpo.2010.11.001
De Felice LJ, Glennon RA, Negus SS (2014) Synthetic cathinones: chemical phylogeny, physiology, and neuropharmacology. Life Sci 97:20–26. doi:10.1016/j.lfs.2013.10.029
Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 37:1192–1203. doi:10.1038/npp.2011.304
Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M et al (2013) Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology 38:552–562. doi:10.1038/npp.2012.204
Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470. doi:10.1111/j.1476-5381.2012.02145.x
Gregg RA, Rawls SM (2014) Behavioral pharmacology of designer cathinones: a review of the preclinical literature. Life Sci 97:27–30. doi:10.1016/j.lfs.2013.10.033
Schifano F (2015) Novel psychoactive substances (NPS): clinical and pharmacological issues. Drugs Alcohol Today 15:21–27. doi:10.1108/DAT-10-2014-0035
Schifano F (2014) Novel psychoactive substances also known as ‘legal highs’. In: Davies SC (ed) Annual report of the Chief Medical Officer 2013. Public mental health priorities: investing in the evidence. Department of Health, London. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/413196/CMO_web_doc.pdf (2014). Accessed 22 Nov 2015
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32–41
Iversen L, White M, Treble R (2014) Designer psychostimulants: pharmacology and differences. Neuropharmacology 87:59–65. doi:10.1016/j.neuropharm.2014.01.015
Farrè M, Papaseit E, Pérez-Mañá C, Pujadas M, Fonseca F, Torrens M, De La Torre R, Farre M (2014) Human pharmacology of mephedrone: a dose-finding pilot study. College on Problems of Drug Dependence Meeting, San Juan
Hyde JF, Browning E, Adams R (1928) Synthetic homologs of d,I-Ephedrine. J Am Chem Soc 50:2287–2292. doi:10.1021/ja01395a032
L’Italien YJ, Park H, Rebstock LC (1957) Methylaminopropiophenone compounds and methods for producing the same. US Patent 2:802–865
de Burnaga Sanchez SJ (1929) Sur un homologue de l’ephedrine. Bull Soc Chim Fr 45:284–286
Meltzer P, Butler D, Deschamps JR, Madras BK (2006) 1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49:1420–1432
Boehringer. Boehringer Ingelheim Patent for MDPV (1969) http://catbull.com/alamut/Bibliothek/Boehringer_MDPV_Patent.htm. Accessed 20 Nov 2015
Carroll FI, Blough BE, Abraham P, Mills AC, Holleman JA, Wolckenhauer SA, Decker AM, Landavazo A, McElroy KT, Navarro HA, Gatch MB, Forster MJ (2009) Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem 52:6768–6781. doi:10.1021/jm901189z
Bondarev ML, Bondareva TS, Young R, Glennon RA (2003) Behavioral and biochemical investigations of bupropion metabolites. Eur J Pharmacol 474:85–93
Vento AE, Schifano F, Gentili F, Pompei F, Corkery JM, Kotzalidis GD et al (2013) Bupropion perceived as a stimulant by two patients with a previous history of cocaine misuse. Ann Ist Super Sanita 49:402–405. doi:10.4415/ANN_13_04_14
Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Flesland LH, Mannonen M, Majava A, Peltoniemi T, Pasinetti M, Pezzolesi C, Scherbaum N, Siemann H, Skutle A, Torrens M, van der Kreeft P, Iversen E, Schifano F (2012) Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry 39:221–226. doi:10.1016/j.pnpbp.2012.07.011
Coppola M, Mondola R (2012) 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol Lett 208:12–15. doi:10.1016/j.toxlet.2011.10.002
Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33–42. doi:10.1007/s13181-011-0193-z
Dargan PI, Albert S, Wood DM (2010) Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. QJM 103:875–879. doi:10.1093/qjmed/hcq134
Corkery JM, Schifano F, Ghodse AH (2012) Mephedrone-related fatalities in the United Kingdom: contextual, clinical and practical issues. In: Gallelli L (ed) Pharmacology. InTech, Rijeka, Croatia, pp 355–380. doi:10.5772/32935. http://www.intechopen.com/books/pharmacology/mephedrone-related-fatalities-in-the-united-kingdom-contextual-clinical-and-practical-issues. Accessed 15 Nov 2015
Schifano F, Corkery J, Ghodse AH (2012) Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone; ‘meow meow’) in the UK. J Clin Psychopharmacol 32:710–714. doi:10.1097/JCP.0b013e318266c70c
Corkery JM, Schifano F, Oyefeso A, Ghodse AH, Tonia T, Naidoo V, Button J (2011) ‘Bundle of fun’ or ‘bunch of problems’? Case series of khat-related deaths in the UK. Drugs Educ Prev Policy 18:408–425. doi:10.3109/09687637.2010.504200
Loi B, Corkery JM, Claridge H, Goodair C, Chiappini S, Gimeno Clemente C, Schifano F (2015) Deaths of individuals aged 16–24 years in the UK after using mephedrone. Hum Psychopharmacol 30:225–232. doi:10.1002/hup.2423
Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, Davey Z, Corkery J, Siemann H, Scherbaum N, Farre’ M, Torrens M, Demetrovics Z, Ghodse AH; Psychonaut Web Mapping; ReDNet Research Groups (2011) Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 214:593–602. doi:10.1007/s00213-010-2070-x
McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18:8417–8422
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2014) Perspectives on drugs: injection of synthetic cathinones. Perspectives on Drugs Series, Lisbon, 27 May. http://www.emcdda.europa.eu/topics/pods/synthetic-cathinones-injection. Accessed 15 Nov 2015
Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, Ennis O, O’Donnell K, Keenan E, De Gascun C, Lyons F, Ward M, Danis K, Glynn R, Waters A, Fitzgerald M, outbreak control team (2015) Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015. Eurosurveill 20; issue 40; art 1. doi:10.2807/1560-7917.ES.2015.20.40.30036
Sellors K, Jones A, Chan B (2014) Death due to intravenous use of α-pyrrolidinopentiophenone. Med J Aust 201:601–603
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2015) Injection of synthetic cathinones. http://www.emcdda.europa.eu/topics/pods/synthetic-cathinones-injection. Accessed 29 Nov 2015
Gannon BM, Reichard EE, Fantegrossi WE (2014) Psychostimulant abuse and HIV infection: cocaine, methamphetamine, and “bath salts” cathinone analogues. Curr Addict Rep 1:237–242
Bourne A, Reid D, Hickson F, Rueda ST, Weatherburn P (2014) The Chemsex study: drug use in sexual settings among gay & bisexual men in Lambeth, Southwark & Lewisham. Sigma Research, London School of Hygiene & Tropical Medicine, London
Kirby T, Thornber-Dunwell M (2013) High-risk drug practices tighten grip on London gay scene. Lancet 381:101–102
McCall H, Adams N, Mason D, Willis J (2015) What is chemsex and why does it matter? It needs to become a public health priority. BMJ 351:h5790
Maskell PD, De Paoli G, Seneviratne C, Pounder DJ (2011) Mephedrone (4-methylmethcathinone)-related deaths. J Anal Toxicol 35:188–191
Torrance H, Cooper G (2010) The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 202:e62–e63. doi:10.1016/j.forsciint.2010.07.014
Warrick BJ, Wilson J, Hedge M, Freeman S, Leonard K, Aaron C (2012) Lethal serotonin syndrome after methylone and butylone ingestion. J Med Toxicol 8:65–68. doi:10.1007/s13181-011-0199-6
Lee D, Chronister CW, Hoyer J, Goldberger BA (2015) Ethylone-related deaths: toxicological findings. J Anal Toxicol 39:567–571. doi:10.1093/jat/bkv053
Dy I, Lankford S (2015) Bath salt thrombosis. J Clin Toxicol 5:230. doi:10.4172/2161-0495.1000230
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) (2015) EMCDDA–Europol Joint Report on a new psychoactive substance: 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (α-PVP). Publications Office of the European Union, Luxembourg. http://www.emcdda.europa.eu/attachements.cfm/att_242501_EN_TDAS15001ENN.pdf. Accessed 29 Nov 2015
Murray BL, Murphy CM, Beuhler MC (2012) Death following recreational use of designer drug “bath salts” containing 3,4-methylenedioxypyrovalerone (MDPV). J Med Toxicol 8:69–75. doi:10.1007/s13181-011-0196-9
Ojanperä IA, Heikman PK, Rasanen IJ (2011) Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther Drug Monit 33(2):257–263. doi:10.1097/FTD.0b013e318208b693
Young AC, Schwarz ES, Velez LI, Gardner M (2013) Two cases of disseminated intravascular coagulation due to “bath salts” resulting in fatalities, with laboratory confirmation. Am J Emerg Med 31:445.e3-5. doi:10.1016/j.ajem.2012.05.032
Wikström M, Thelander G, Nyström I, Kronstrand R (2010) Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone). J Anal Toxicol 34:594–598
NISRA (2015) Drug related and drug misuse deaths 2004–2014. Northern Ireland Statistics & Research Agency, Belfast. http://www.nisra.gov.uk/archive/demography/publications/drug_deaths/Drug_Tables_14.xls. Accessed 30 Nov 2015
Elliott S, Evans J (2014) A 3-year review of new psychoactive substances in casework. Forensic Sci Int 243:55–60. doi:10.1016/j.forsciint.2014.04.017
Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75:17–33
Halpern JH, Suzuki J, Huertas PE, Passie T (2011) Hallucinogens. In: Addiction medicine. Springer, pp 1083–1098
Sinke C, Halpern JH, Zedler M, Neufeld J, Emrich HM, Passie T (2012) Genuine and drug-induced synesthesia: a comparison. Conscious Cogn 21:1419–1434
Chan RHA, Mendelson JE (2014) Hallucinogens. In: Madras B, Kuhar M (eds) The effects of drug abuse on the human nervous system. Elsevier
Jacob P, Shulgin AT (1994) Structure-activity relationships of classic hallucinogens and their analogs. NIDA Res Monogr 146:74–91
Glennon RA (1996) Classical hallucinogens. In: Schuster CR, Kuhar MJ (eds) Handbook of experimental pharmacology: pharmacological aspects of drug dependence. Springer, Basel, Switzerland, pp 343–371
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181
Ray TS (2010) Psychedelics and the human receptorome. PLoS One 5, e9019
Bulling S, Schicker K, Zhang YW, Steinkellner T, Stockner T, Gruber CW, Boehm S, Freissmuth M, Rudnick G, Sitte HH, Sandtner W (2012) The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. J Biol Chem 287:18524–18534. doi:10.1074/jbc.M112.343681
Ede F, Szabo A, Winkelman MJ, Luna LE, McKenna DJ (2013) A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. J Neural Transm 120:1295–1303
Shulgin A, Shulgin A (1997) TIHKAL: the continuation. Transform Press. http://www.erowid.org/library/books_online/tihkal. Accessed 15 Sept 2014
Orsolini L, Papanti GD, Francesconi G, Schifano F (2015) Mind navigators of chemicals’ experimenters? A web-based description of e-psychonauts. Cyberpsychol Behav Soc Netw 18:296–300. doi:10.1089/cyber.2014.0486
Monitoring the Future Study (2014) Trends in prevalence of various drugs for 8th graders, 10th graders, and 12th graders. http://www.drugabuse.gov/drugs-abuse/hallucinogens. Accessed 20 Nov 2015
National Survey on Drug Use and Health: Trends in prevalence of various drugs for ages 12 or older, ages 12 to 17, ages 18 to 25, and ages 26 or older. http://www.drugabuse.gov/drugs-abuse/hallucinogens (2014). Accessed 20 Nov 2015
Heinrich C (2002) Magic mushrooms in religion and alchemy. Park Street Press, Rochester
Winkelman MJ, Roberts TB (2007) Psychedelic medicine: new evidence for hallucinogenic substances as treatments. Praeger Publishers, Westport
Studerus EA (2012) Prediction of psilocybin response in healthy volunteers. PLoS One 7, e30800
Gable RS (2007) Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 102:24–34
Hoffman A (1980) LSD: my problem child. McGraw-Hill, London
US Department of Justice, Drug Enforcement Administration. LSD in the United States. http://www.usdoj.gov/dea/pubs/lsd/toc.htm. Accessed 13 Nov 2015
Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, Wallach J, Halbertstadt AL (2015) Return of the lysergamides. Part I: analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD). Drug Test Anal. doi:10.1002/dta.1884
Flodrops H, Houdon L, Harvet G, Enaud L, Renouil M (2006) Voluntary intoxication by D-lysergic acid amide (LSA) in a 15-year-old teenager via Internet: new fact of society. Arch Pediatr 13:1158–1159
Barker SA, Monti JA, Christian ST (1981) N,N-Dimethyltryptamine: an endogenous hallucinogen. Int Rev Neurobiol 22:83–110
Guichhait RB (1976) Biogenesis of 5-methoxy-N,N-dimethyltryptamine in human pineal gland. J Neurochem 26:187–190
Kärkkäinen J, Räisäinen M, Naukarinen H, Spoov J, Rimon R (1988) Urinary excretion of free bufotenin by psychiatric patients. Biol Psychiatry 24:441–446
Cimino G, De Stefano S (1978) Chemistry of Mediterranean Gorgonians. Simple indole derivatives from Paramuricea chamaeleon. Comptes Rendus Biochem Physiol Ser C 61:361–362
Collins M (2011) Some new psychoactive substances: precursor chemicals and synthesis-driven end-products. Drug Test Anal 3:404–416
Koike Y, Wada K, Kusano G, Nozoe S, Yokoyama K (1981) Isolation of psilocybin from Psilocybe argentipes and its determination in specimens of some mushrooms. Lloydia 44:362–365
Mckenna DJ, Towers GHN (1984) Biochemistry and pharmacology of tryptamines and beta-carbolines: a minireview. J Psychoactive Drugs 16:347–358
Schultes RE (1979) Hallucinogenic plants: their earliest botanical descriptions. J Psychedelic Drugs 11:13–24
Brandes JL, Kudrow D, Stark SR, O’Carroll CP, Adelman JU, O’Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE (2007) Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 297:1443–1454
Hoffmann A, Heim R, Brack A, Kobel H, Frey A, Ott H, Petrzilka T, Troxler F (1959) Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen. Helv Chim Acta 42:1557–1572
Sanders B, Lankenau SE, Bloom JJ, Hathazi D (2008) ‘Research chemicals’: tryptamine and phenylamine use among high-risk youth. SUM 43:389–402
UNODC (United Nations Office on Drugs and Crime) (2013) The challenge of new psychoactive substances. United Nations Office on Drugs and Crime, Vienna
UNODC (United Nations Office on Drugs and Crime) (2013) Early Warning Advisory on New Psychoactive Substances (NPS). October 2013 update
UNODC (United Nations Office on Drugs and Crime) (2014) Global synthetic drugs assessment. https://www.unodc.org/documents/scientific/2014_Global_Synthetic_Drugs_Assessment_web.pdf. Accessed 8 Dec 2015
Arunotayanun W, Dalley JW, Huang XP, Setola V, Treble R, Iversen L, Roth BL, Gibbons S (2013) An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging ‘Novel Psychoactive Drugs’. Bioorg Med Chem Lett 23:3411–3415
The Misuse of Drugs Act 1971 (Modification) Order 2005. Office of Public Sector Information. Retrieved 23 September 2014
Dargan PI, Wood DM (2013) Novel psychoactive substances: classification, pharmacology and toxicology. Elsevier
Lessin AW, Long RF, Parkes MW (1965) Central stimulant actions of α-alkyl substituted tryptamine in mice. Br J Pharmacol 24:49–67
Pierce PA, Peroutka SJ (1989) Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 97:118–122
Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shuldin AT, Daley PF, Ruoho AE (2009) Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm 116:1591–1599
Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE (2009) The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323:934–937
Su TP, Hayashi T, Vaupel DB (2009) When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Sci Signal 2:12
Sogawa C, Sogawa N, Tagawa J, Fujino A, Ohyama K, Asanuma M, Funada M, Kitayama S (2007) 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicol Lett 170:75–82
Lyttle T, Goldstein D, Gartz J (1996) Bufo. Toads and bufotenine: fact and fiction surrounding an alleged psychedelic. J Psychoactive Drugs 28:267–290
Shen HW, Jiang XL, Winter JC, Yu AM (2010) Psychedelic 5-methoxy-N,N-dimethyltryptamine: metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab 11:659–666
Ujvary I (2014) Psychoactive natural products: overview of recent developments. Ann Ist Super Sanità 50:12–27
Ambrose JB, Bennett HD, Lee HS, Josephson SA (2010) Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion. Neurologist 16:199–202
Bosak A, LoVecchio F, Levine M (2013) Recurrent seizures and serotonin syndrome following “2C-I” ingestion. J Med Toxicol 9:196–198
Topeff JM, Ellsworth H, Willhite LA, Cole JB, Edwards EM (2011) A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Toxicol 49:526
Nelson ME, Bryant SM, Aks SE (2014) Emerging drugs of abuse. Emerg Med Clin N Am 1–28. doi:10.1016/j.emc.2013.09.001
Corazza O, Schifano F, Farre M, Deluca P, Davey Z, Torrens M, Demetrovics Z, Di Furia L, Flesland L, Siemann H, Skutle A, Van Der Kreeft P, Scherbaum N (2011) Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 6:125–129
DEA US (Drug Enforcement Administration) (2013) Midyear Report 2013. Office of Diversion Control: National Forensic Laboratory Information System. US Drug Enforcement Administration, Springfield, VA. Accessed 1 Oct 2015
Uchiyama N, Shimokawa Y, Matsuda S, Kawamura M, Kikura-Hanajiri R, Goda Y (2014) Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 2,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products. Forensic Toxicol 32:105–115
Caldicott DG, Bright SJ, Barratt MJ (2013) NBOMe – a very different kettle of fish. Med J Aust 199:322–323
Poklis JI, Devers KG, Arbefeville EF, Pearson JM, Houston E, Poklis A (2014) Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 234:e14–e20
Ralston N, Davies I (2015) Teen jumps to his death after $1.50 drug hit 2013. http://www.smh.com.au/nsw/teen-jumps-to-his-death-after-150-drug-hit-20130606-2nrpe.html#ixzz35BP7Ymmx. Accessed 1 Oct 2015
Walterscheid JP, Phillips GT, Lopez AE, Gonsoulin MI, Chen HH, Sanchez LA (2014) Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. Am J Forensic Med Pathol 35:20–25
Braden MR, Parrish JC, Naylor JC, Nichols DE (2006) Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 70:1956–1964. doi:10.1124/mol.106.028720
Halberstadt AL, Geyer MA (2014) Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 77(February):200–207. doi:10.1016/j.neuropharm.2013.08.025
Wood DM, Sedefov R, Cunningham A, Dargan PI (2015) Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol (Phila) 53:85–92. doi:10.3109/15563650.2015.1004179
Kueppers VB, Cooke CT (2015) 25I-NBOMe related death in Australia: a case report. Forensic Sci Int 249:e15–e18. doi:10.1016/j.forsciint.2015.02.010
Lowe LM, Peterson BL, Couper FJ (2015) A case review of the first analytically confirmed 25I-NBOMe-related death in Washington State. J Anal Toxicol 39:668–671. doi:10.1093/jat/bkv092
Suzuki J, Poklis JL, Poklis A (2014) “My friend said it was good LSD”: a suicide attempt following analytically confirmed 25I-NBOMe ingestion. J Psychoactive Drugs 46:379–382. doi:10.1080/02791072.2014.960111
Suzuki J, Dekker MA, Valenti ES, Arbelo Cruz FA, Correa AM, Poklis JL, Poklis A (2015) Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. Psychosomatics 56:129–139. doi:10.1016/j.psym.2014.11.002
Lawn W, Barratt M, Williams M, Horne A, Winstock A (2014) The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol 28:780–788. doi:10.1177/0269881114523866
Shanks KG, Sozio T, Behonick GS (2015) Fatal intoxications with 25B-NBOMe and 25I-NBOMe in Indiana during 2014. J Anal Toxicol 39:602–606. doi:10.1093/jat/bkv058
Wood DM, Davies S, Puchnarewicz M, Button J, Archer R, Ovaska H, Ramsey J, Lee T, Holt DW, Dargan PI (2010) Recreational use of mephedrone (4-methylmethcathinone, 4-MMC) with associated sympathomimetic toxicity. J Med Toxicol 6:327–330. doi:10.1007/s13181-010-0018-5
Wood DM, Davies S, Puchnarewicz M, Button J, Archer R, Ramsey J, Lee T, Holt DW, Dargan PI (2009) Recreational Use of 4-methylmethcathinone (4-MMC) presenting with sympathomimetic toxicity and confirmed by toxicological screening. Clin Toxicol 47:733
Wood DM, Greene SL, Dargan PI (2010) Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg Med J 28:280–282
Fass JA, Fass AD, Garcia AS (2012) Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann Pharmacother 46:436–441. doi:10.1345/aph.1Q628
Wilson B, Tavakoli H, DeCecchis D, Mahadev V (2013) Synthetic cannabinoids, synthetic cathinones, and other emerging drugs of abuse. Psychiatr Ann 43:558–564
Mas-Morey P, Visser MH, Winkelmolen L, Touw DJ (2013) Clinical toxicology and management of intoxications with synthetic cathinones (“bath salts”). J Pharm Pract 26:353–357. doi:10.1177/0897190012465949
Winstock AR, Marsden J, Mitcheson L (2010) What should be done about mephedrone? BMJ 340:c1605. doi:10.1136/bmj.c1605
Newcombe R (2009) Mephedrone: the use of mephedrone (M-cat,meow) in Middlesbrough. Lifeline Publications, Manchester. http://www.lifeline.org.uk/articles/the-use-of-mephedrone-m-cat-meow-in-middlesbrough/. Accessed 29 Nov 2015
Acknowledgements/Funding Statements
This paper was supported in part by grants of the European Commission (Drug Prevention and Information Programme 2014-16, contract no. JUST/2013/DPIP/AG/4823, EU-MADNESS project). Further financial support was provided by the EU Commission-targeted call on cross border law enforcement cooperation in the field of drug trafficking – DG Justice/DG Migrations and Home Affairs (JUST/2013/ISEC/DRUGS/AG/6429) Project EPS/NPS (Enhancing Police Skills concerning Novel Psychoactive Substances; NPS).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Schifano, F., Orsolini, L., Papanti, D., Corkery, J. (2016). NPS: Medical Consequences Associated with Their Intake. In: Baumann, M.H., Glennon, R.A., Wiley, J.L. (eds) Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences, vol 32. Springer, Cham. https://doi.org/10.1007/7854_2016_15
Download citation
DOI: https://doi.org/10.1007/7854_2016_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52442-9
Online ISBN: 978-3-319-52444-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)